ArticlePharmaceuticals (Basel, Switzerland)2025
Model-Based Evaluation of HangAmDan-B1 and Afatinib Combination Therapy in HCC827 Xenograft Mice with Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
Sung-Yoon Yang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.